Ziccum to attend BIO-Europe Spring in Basel - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelande

Ziccum to attend BIO-Europe Spring in Basel

MFN Publicerad: 17 Mar 2023 08:40
Ziccum

Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall will attend the BIO-Europe Spring 2023 Conference in Basel, Switzerland March 20 – 22. The event attracts pharma and biopharma corporations from across the globe. The latest updates from Ziccum technology development will be presented at meetings at the event.

On March 20 – 22, Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall will be onsite in Basel, Switzerland at one of the world’s leading pharma and biotech events - BIO-Europe Spring 2023.

The latest updates from Ziccum projects and technology development will be presented at partnering meetings, promoting the company’s unique LaminarPace drying technology for vaccines and biologics.

CEO Ann Gidner: “we look forward to attending BIO-Europe and sharing our latest findings and results with both existing partners and new contacts. It will certainly be a dynamic and productive event.”

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: [email protected]
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: [email protected]
Mobile: +46 706 45 08 75
 
Ziccum’s Certified Adviser is Erik Penser Bank AB

About Ziccum

Ziccum is developing LaminarPaceTM, a unique ambient drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPaceTM uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum to attend BIO-Europe Spring in Basel

Bifogade filer

Ziccum to attend BIO-Europe Spring in Baselhttps://storage.mfn.se/c55a6def-c2dd-480d-8184-05bab2abdd02/ziccum-to-attend-bio-europe-spring-in-basel.pdf

Nyheter om Ziccum

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

Jämförelse: Vilken är Sveriges bästa fondrobot?Guide: Så börjar du spara i fonder som nybörjareTopplistor: Fonderna med bäst avkastning just nu
STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Ziccum

Senaste nytt